Valneva SE: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Intercell AG Approves Proposed Merger of Equals with Vivalis SA to Create Valneva SE
Vivalis SA announced that Intercell AG`s Extraordinary General Meeting (EGM) approved all resolutions, and the proposed merger of equals with Vivalis to create Valneva.
Latest Developments for Valneva SE
- Valneva SE confirms FY 2014 outlook guidance
- Valneva SE announces first ever marketing approval in Europe for vaccine produced in EB66 cell line
- Valneva SE announces first marketing authorization for human vaccine produced in EB66 cell line
- Valneva SE announces approval and launch in South America of second veterinary vaccine produced in EB66 cell line
Latest Key Developments in Biotechnology
- Share this
- Digg this